Affiliation: President, Genuine Biotech ( China)
Speech Title: Azvudine, a Novel Nucleoside as Effective Treatment for HIV and COVID-19
Infections With Potential for Liver Cancer
Biography:Genuine Biotech as
President and responsible for all aspects of company business including
corporate strategy, R&D, financing etc. Max has extensive experiences in
business development globally and more than 25-years of experiences as a
manager of drug discovery programs spanning from early (Target Selection and
Validation, Lead Identification) to late (Lead Optimization and candidate
selection) stages; led programs that advanced multiple compounds into human
clinic trials (two completed Phase 2b POC studies); experiences in therapeutic
areas including diabetes, dyslipidemia, hepatitis B and C, liver cancer, liver
fibrosis, anemia, viral and bacterial infections; extensive knowledge of
Structure-based Drug Design, Medicinal Chemistry, Drug Delivery, Prodrugs,
Liver targeting Strategies, Combinatorial, Heterocyclic and Nucleoside
Chemistry; more than five years of managing drug discovery programs executed at
various CROs. His research activities have led to 91 publications and 60
patents.
